NEWRON PHARMACEUTICALS
Newron Pharmaceuticals S.p.A. is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. Xadago® (safinamide) has received marketing authorization for the treatment of Parkinson’s disease in the European Union, Switzerland and the USA, and is commercialized by Newron’s Partner Zambon. US WorldMeds holds the commercialization rights in the USA. Meiji Seika, in collaboration with Eisai, has the rights ... to develop and commercialize the compound in Japan and other key Asian territories. In addition to Xadago® for Parkinson’s disease, Newron has a strong pipeline of promising treatments for rare disease patients at various stages of clinical development, including sarizotan for patients with Rett syndrome and ralfinamide for patients with specific rare pain indications. Newron is also developing Evenamide as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia. Founded in 1999, Newron is headquartered in Bresso, near Milan, Italy, with a subsidiary in Morristown, NJ, USA. The Company is listed on the SIX Swiss Exchange, trading symbol NWRN.
NEWRON PHARMACEUTICALS
Industry:
Biopharma Biotechnology Health Care Medical
Founded:
1999-01-01
Address:
Bresso, Lombardia, Italy
Country:
Italy
Website Url:
http://www.newron.com
Total Employee:
11+
Status:
Active
Contact:
+39026103461
Total Funding:
129.43 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Content Delivery Network Font Awesome Domain Not Resolving Microsoft Exchange Online Amazon Office 365 Mail
Similar Organizations
Accent Therapeutics
Accent Therapeutics is a biopharmaceutical company.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Enterin
Philadelphia-based biotechnology company .
Faron Pharmaceuticals
Faron Pharmaceuticals is a biopharmaceutical company engaged in the biotechnology and medical research industry.
Jenrin Discovery
Jenrin Discovery is a biopharmaceutical Company.
Minerva Neuroscience
Minerva Neurosciences is a clinical-stage biopharmaceutical company
Ocugen
Ocugen is a clinical stage biopharmaceutical company.
Current Advisors List
Board_member
Current Employees Featured
Stefan Weber CEO @ Newron Pharmaceuticals
CEO
Ravi Anand CMO @ Newron Pharmaceuticals
CMO
Roberto Galli Vice President Finance @ Newron Pharmaceuticals
Vice President Finance
2012-07-01
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2012-06-13 | NeuroNova | NeuroNova acquired by Newron Pharmaceuticals | N/A |
| 2008-02-11 | Hunter-Fleming Ltd | Hunter-Fleming Ltd acquired by Newron Pharmaceuticals | N/A |
Investors List
TVM Capital
TVM Capital investment in Series B - Newron Pharmaceuticals
3i Group
3i Group investment in Series B - Newron Pharmaceuticals
HBM Partners
HBM Partners investment in Series B - Newron Pharmaceuticals
Apax Partners
Apax Partners investment in Series B - Newron Pharmaceuticals
Atlas Venture
Atlas Venture investment in Series B - Newron Pharmaceuticals
Apax Partners
Apax Partners investment in Venture Round - Newron Pharmaceuticals
3i Group
3i Group investment in Venture Round - Newron Pharmaceuticals
Atlas Venture
Atlas Venture investment in Venture Round - Newron Pharmaceuticals
3i Group
3i Group investment in Venture Round - Newron Pharmaceuticals
Official Site Inspections
http://www.newron.com Semrush global rank: 3.25 M Semrush visits lastest month: 5.08 K
- Host name: ec2-52-17-142-199.eu-west-1.compute.amazonaws.com
- IP address: 52.17.142.199
- Location: Dublin Ireland
- Latitude: 53.3338
- Longitude: -6.2488
- Timezone: Europe/Dublin
- Postal: D02
More informations about "Newron Pharmaceuticals"
Annual Report 2023 - Newron Pharmaceuticals
•023 ESG Report: Newron follows the most recent edition of the Directive on Information re2 - lating to Corporate Governance of SIX Exchange Regulation (SER) Table of ContentsSee details»
Newron Pharmaceuticals - Crunchbase Company …
Newron Pharmaceuticals S.p.A. is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and …See details»
Reports and Presentations | Newron Pharmaceuticals
Welcome to Newron’s download centre. This area contains financial reports, presentations, webcasts and more. Download the Half Year Report 2022 below. Download the Annual Report …See details»
Annual Report 2020 - Newron Pharmaceuticals
• Newron remains on track to initiate its pivotal Phase III program in Q3 2021 • Newron continues to evaluate potential options for partnering/co-developing evenamide Xadago®/safinamide – …See details»
Newron Pharmaceuticals S.p.A. - Devex
Newron Pharmaceuticals S.p.A. is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system.See details»
Company Newron Pharmaceuticals S.p.A.
Dec 31, 2004 · Newron Pharmaceuticals SpA is an Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and …See details»
Executive Director & CEO at Newron Pharmaceuticals
Stefan Weber was appointed Chief Executive Officer and Executive Director of Newron in 2012. He had been Chief Financial Officer of the Company since April 2005. Stefan holds a master’s degree in business management from …See details»
Newron provides H1 2022 results and updates on
Sep 15, 2022 · Newron Pharmaceuticals today announces its half-year 2022 financial results and operational highlights and updates its R&D and business activities.See details»
Newron Pharmaceuticals - Edison Group
Register with Edison to follow Newron Pharmaceuticals. Newron Pharmaceuticals is focused on the central nervous system. Xadago for Parkinson’s disease (PD) is sold in Europe, Japan, the United States and other regions. Evenamide, a …See details»
Annual Report 2022 - Newron Pharmaceuticals
Newron is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. The company’s shares …See details»
Newron Pharmaceuticals - Craft
Jul 19, 2024 · Newron Pharmaceuticals has 5 employees across 5 locations and €9.06 m in annual revenue in FY 2023. See insights on Newron Pharmaceuticals including office …See details»
Newron Announces 2020 Financial Results - Business Wire
Mar 16, 2021 · Newron Pharmaceuticals S.p.A.(SIX: NWRN), announces 2020 financial results. Conference call today on March 16, 2021 at 03:00 pm CET.See details»
Newron Announces 2022 Financial Results and Provides Outlook …
Mar 14, 2023 · MILAN-- ( BUSINESS WIRE )--Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel …See details»
Newron Pharmaceuticals - Overview, News & Similar companies
May 13, 2024 · Newron Pharmaceuticals contact info: Phone number: +39 26103461 Website: www.newron.com What does Newron Pharmaceuticals do? Founded in 1999 and …See details»
Change in Newron Board of Directors | Newron Pharmaceuticals
Dec 1, 2021 · Newron (SIX: NWRN, XETRA: NP5) is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral …See details»
Newron - Products, Competitors, Financials, Employees, …
Newron develops generative AI technology, providing solutions for decision-making and productivity in various sectors. The company offers language models, AI deployments, and …See details»
Newron Announces Half-Year 2021 Results - Business Wire
Sep 16, 2021 · Newron (SIX: NWRN, XETRA: NP5) is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral …See details»
Newron extends Senior Management team and strengthens …
Jul 1, 2022 · Newron (SIX: NWRN, XETRA: NP5) is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral …See details»
Request your access to gfknewron
Gfk newron supercharges your ability to access and utilize key business intelligence across your entire organization. By interpreting market, consumer, and brand data, you’ll have a …See details»
Newron announces 2020 financial results and provides outlook for …
Milan, Italy, March 16, 2021 – Newron Pharmaceuticals S.p.A. (“Newron(SIX: NWRN, XETRA: ”) NP5), a biopharmaceutical company focused on the development of novel therapies for …See details»